Plus Therapeutics, Inc. announced on September 22, 2025, that it received notice of an additional advance payment of $1.9 million from the Cancer Prevention and Research Institute of Texas (CPRIT). This payment is part of the company’s previously awarded $17.6 million grant.
This marks the second non-dilutive financing received from CPRIT, following a $1.6 million payment announced in July 2025. An additional $1.9 million in funding is expected over the next 12 months, providing a steady source of non-dilutive capital.
The funding supports and accelerates the company’s clinical development of REYOBIQ™ for the ReSPECT-LM dose optimization trial. It also further develops the company’s CNSide LM diagnostic test as a key pivotal trial endpoint, strengthening the company's capital position.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.